This list is an analysis based on recent market events. It's not an investment recommendation.
About
Alpha Cognition Inc., a clinical stage biopharmaceutical company, engages in the development of treatments for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). The company offers ZUNVEYL (benzgalantamine) for the treatment of mild-to-moderate Alzheimer's disease and mild traumatic brain injury. It also develops ALPHA-0602, a gene therapy for the treatment of ALS; and ALPHA-0702 and ALPHA-0802, a granulin epithelin motifs for the treatment of neurodegenerative diseases. The company was formerly known as Crystal Bridge Enterprises Inc. and changed its name to Alpha Cognition Inc. in March 2021. Alpha Cognition Inc. was founded in 2000 and is headquartered in Vancouver, Canada.
The current price of ACOG.CN is C$8.16 CAD — it has increased by +12.55% in the past 24 hours. Watch Alpha Cognition stock price performance more closely on the chart.
What is Alpha Cognition stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Alpha Cognition stocks are traded under the ticker ACOG.CN.
What is Alpha Cognition revenue for the last year?▼
Alpha Cognition revenue for the last year amounts to 0 CAD.
What is Alpha Cognition net income for the last year?▼
ACOG.CN net income for the last year is -20.31M CAD.
How many employees does Alpha Cognition have?▼
As of April 29, 2026, the company has 5 employees.
In which sector is Alpha Cognition located?▼
Alpha Cognition operates in the Health & Wellness sector.
When did Alpha Cognition complete a stock split?▼
The last stock split for Alpha Cognition was on November 05, 2024 with a ratio of 1:25.
Where is Alpha Cognition headquartered?▼
Alpha Cognition is headquartered in Vancouver, Canada.